Regulatory Blog

As biosimilar development continues to advance, regulatory expectations extend well beyond demonstrating analytical similarity and clinical performance. Product presentation—including the container closure system (CCS) and device constituent parts—has become an important aspect of ensuring product quality, usability, and patient safety throughout the product lifecycle. The U.S. Food and Drug Administration (FDA) has published the draft guidance Biosimilar and Interchangeable

Timely access to innovative medicines and biosimilars is an important objective for regulatory authorities worldwide. Collaborative assessment models enable regulators to share scientific expertise, reduce duplication of effort, and accelerate the availability of high-quality, safe, and effective medicines for patients. International work-sharing initiatives also promote regulatory convergence while maintaining robust scientific evaluation standards. The Medicines and Healthc